Ehrenreich, Hannelore

[["dc.bibliographiccitation.firstpage","217"],["dc.bibliographiccitation.lastpage","236"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Sirén, Anna-Leena"],["dc.contributor.editor","Felthous, Alan"],["dc.contributor.editor","Sass, Henning"],["dc.date.accessioned","2017-09-07T11:46:20Z"],["dc.date.available","2017-09-07T11:46:20Z"],["dc.date.issued","2008"],["dc.identifier.gro","3150480"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7249"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.publisher","Wiley"],["dc.publisher.place","Chichester"],["dc.relation.isbn","978-0-470-01185-0"],["dc.relation.ispartof","The International Handbook of Psychopathic Disorders and the Law, Vol. 1"],["dc.title","Brain trauma"],["dc.type","book_chapter"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","427"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Cerebral Blood Flow and Metabolism"],["dc.bibliographiccitation.lastpage","430"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Heyer, Andrea"],["dc.contributor.author","Hasselblatt, Martin"],["dc.contributor.author","von Ahsen, Nicolas"],["dc.contributor.author","Häfner, Heinz"],["dc.contributor.author","Sirén, Anna-Leena"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:18Z"],["dc.date.available","2017-09-07T11:46:18Z"],["dc.date.issued","2005"],["dc.description.abstract","Gender differences in neuropsychiatric disease are recognized but not well understood. Investigating the survival of primary rat hippocampal neurons in culture, we found significant and inverted gender differences on normoxia versus hypoxia. Male cells were more resistant under normoxia but more vulnerable under hypoxia than female cells. Male vulnerability pattern was acquired in cells from neonatally testosterone-primed females. Estrogens, acting via membrane receptors, had a higher neuroprotective power in male neurons, explained at least in part by the pronounced increase in estrogen receptor beta/alpha ratio during hypoxia in male cells only."],["dc.identifier.doi","10.1038/sj.jcbfm.9600056"],["dc.identifier.gro","3150469"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7237"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0271-678X"],["dc.subject","aromatase; estrogen receptor alpha; estrogen receptor beta; hippocampus; sex; testosterone"],["dc.title","In vitro gender differences in neuronal survival on hypoxia and in 17 beta-estradiol-mediated neuroprotection"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","136"],["dc.bibliographiccitation.journal","Neurobiology of Learning and Memory"],["dc.bibliographiccitation.lastpage","150"],["dc.bibliographiccitation.volume","150"],["dc.contributor.author","Dere, Ekrem"],["dc.contributor.author","Ronnenberg, Anja"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.author","Arinrad, Sahab"],["dc.contributor.author","Schmidt, Manuela"],["dc.contributor.author","Zeisberg, Elisabeth"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2020-12-10T15:20:34Z"],["dc.date.available","2020-12-10T15:20:34Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.nlm.2018.02.023"],["dc.identifier.issn","1074-7427"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72715"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Cognitive, emotional and social phenotyping of mice in an observer-independent setting"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","239"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Alcohol and Alcoholism"],["dc.bibliographiccitation.lastpage","242"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Hasselblatt, Martin"],["dc.contributor.author","Krieg-Hartig, Christian"],["dc.contributor.author","Hüfner, Michael"],["dc.contributor.author","Halaris, Angelos"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:45:48Z"],["dc.date.available","2017-09-07T11:45:48Z"],["dc.date.issued","2003"],["dc.description.abstract","Aims: Testosterone synthesis in chronic alcoholics is affected by a variety of mechanisms. Little is known about the reversibility of these changes upon abstinence and available data on circulating hormone levels are incomplete and inconsistent. Methods: Serum concentrations of free testosterone, total testosterone, and luteinizing hormone (LH) were determined in 18 male non-cirrhotic chronic alcoholics on days 2, 22, 82 and 127 of strictly controlled abstinence, as well as in a group of 20 healthy age-matched controls. Results: Higher total testosterone concentrations were found in alcoholics on the second day of abstinence, as compared to controls (7.1 ± 1.9 vs 5.6 ± 1.4 ng/ml) and throughout the whole observation period. Correspondingly, free testosterone concentrations were increased over control levels on day 2 (40.0 ± 12.1 vs 29.7 ± 8.1 pg/ml) and stayed elevated in the presence of augmented concentrations of LH [4.5 U/l (range 1.6–9.5 U/l) vs 2.0 U/l (range 0.8–8.1 U/l)] for up to 127 days of strictly controlled abstinence. Conclusions: Sustained increases in serum free and total testosterone levels in the presence of inadequately raised LH concentrations point towards persisting disturbances of the hypothalamic–pituitary–gonadal axis in male alcoholics upon cessation of drinking."],["dc.identifier.gro","3150460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7226"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0735-0414"],["dc.subject","testosterone; hormone; luteinizing hormone; persistence; hypothalamic-pituitary-gonadal axis; testosterone measurement; serum; alcoholics"],["dc.title","Persistent disturbance of the hypothalamic-pituitary-gonadal axis in abstinent alcoholic men"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","92"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Alcohol and Alcoholism"],["dc.bibliographiccitation.lastpage","102"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Kunert, Hanns-Jürgen"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Kröner-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Krampe, Henning"],["dc.date.accessioned","2017-09-07T11:46:30Z"],["dc.date.available","2017-09-07T11:46:30Z"],["dc.date.issued","2007"],["dc.description.abstract","The hippocampus (HC) is characterized by high vulnerability to noxious influence, but also by a considerable regenerative potential. Although deficits in HC-related functions are among the most commonly reported cognitive sequelae in alcoholism, little and conflicting information is available concerning regeneration upon abstinence. The present study has been designed to evaluate (i) the frequency of measurable dysfunction in so called HC tests and (ii) its predictive value for risk to relapse in a cohort of 50 severely affected chronic alcoholic patients and (iii) to monitor recovery of HC-related functions upon strict abstention from alcohol. Patients underwent a 2-year neuropsychological follow-up including HC-associated tests (Verbal Learning Test, VLT; Nonverbal Learning Test, NVLT; 'City Map Test' of Learning and Memory Test, LGT-3), as well as tests of intelligence and attention in the framework of OLITA (Outpatient Long-Term Intensive Therapy for Alcoholics), a programme with careful abstinence monitoring. At study entry, 30/50 (60%) alcoholics had HC dysfunction which tended to predict a lower long-term abstinence probability (P = 0.058). Of the subgroup that could be followed under conditions of strictly monitored alcohol abstinence (n = 32; age 44.7 +/- 6.2 years; 23 men, 9 women), 53% (17/32) exhibited distinct HC dysfunction at inclusion which returned to normal after 2 years. Patients with initially normal HC function (9/32) and patients with additional brain damage of different aetiologies (6/32) failed to show improvement on HC-related tests. While the former displayed stably normal HC test performance, the latter remained on a performance level below normal. Demonstrating slow but remarkable regeneration of HC functions upon strict abstention from alcohol, our data strongly support abstinence-oriented long-term treatment of alcoholics. The absence of functional recovery in patients with additional causes of brain damage might be explained by the 'dual hit' exhausting the regenerative potential of the HC."],["dc.identifier.doi","10.1093/alcalc/agl104"],["dc.identifier.gro","3150510"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7282"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0735-0414"],["dc.title","Recovery of hippocampus-related functions in chronic alcoholics during monitored long-term abstinence"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Molecular Medicine"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Weissenborn, Karin"],["dc.contributor.author","Begemann, Martin"],["dc.contributor.author","Busch, Markus"],["dc.contributor.author","Vieta, Eduard"],["dc.contributor.author","Miskowiak, Kamilla W."],["dc.date.accessioned","2021-04-14T08:25:17Z"],["dc.date.available","2021-04-14T08:25:17Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1186/s10020-020-00186-y"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81578"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1528-3658"],["dc.relation.issn","1076-1551"],["dc.title","Erythropoietin as candidate for supportive treatment of severe COVID-19"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Biological Psychiatry"],["dc.bibliographiccitation.volume","71"],["dc.contributor.author","Kaestner, Anne"],["dc.contributor.author","Malzahn, Doerthe"],["dc.contributor.author","Bickeboeller, Heike"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T09:11:08Z"],["dc.date.available","2018-11-07T09:11:08Z"],["dc.date.issued","2012"],["dc.format.extent","87S"],["dc.identifier.isi","000302466000276"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26656"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.conference","67th Annual Meeting of the Society-of-Biological-Psychiatry"],["dc.relation.eventlocation","Philadelphia, PA"],["dc.relation.issn","0006-3223"],["dc.title","Introducing ORNI, the 'Odor Recognition, Naming and Interpretation Test', a Simple and Specific Measure of Sensory-Cognitive-Emotional Processing in Schizophrenia"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Stroke"],["dc.contributor.author","Castillo-Gomez, Esther"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:45:44Z"],["dc.date.available","2017-09-07T11:45:44Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1161/strokeaha.115.009725"],["dc.identifier.gro","3150441"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7205"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.title","Response to letter regarding article \"Preexisting serum autoantibodies against the NMDAR subunit NR1 modulate evolution of lesion size in acute ischemic stroke\""],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e647"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Stroke"],["dc.bibliographiccitation.lastpage","e656"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Weißenborn, Karin"],["dc.contributor.author","Prange, Hilmar"],["dc.contributor.author","Schneider, Dietmar"],["dc.contributor.author","Weimar, Christian"],["dc.contributor.author","Wartenberg, Katja"],["dc.contributor.author","Schellinger, Peter D."],["dc.contributor.author","Bohn, Matthias"],["dc.contributor.author","Becker, Harald"],["dc.contributor.author","Wegrzyn, Martin"],["dc.contributor.author","Jähnig, Peter"],["dc.contributor.author","Herrmann, Manfred"],["dc.contributor.author","Knauth, Michael"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Heide, Wolfgang"],["dc.contributor.author","Wagner, Armin"],["dc.contributor.author","Schwab, Stefan"],["dc.contributor.author","Reichmann, Heinz"],["dc.contributor.author","Schwendemann, Günther"],["dc.contributor.author","Dengler, Reinhard"],["dc.contributor.author","Kastrup, Andreas"],["dc.contributor.author","Bartels, Claudia"],["dc.date.accessioned","2017-09-07T11:46:20Z"],["dc.date.available","2017-09-07T11:46:20Z"],["dc.date.issued","2009-12"],["dc.description.abstract","Background and Purpose— Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment of patients with ischemic stroke. Although EPO has been considered to be a safe and well-tolerated drug over 2 decades, recent studies have identified increased thromboembolic complications and/or mortality risks on EPO administration to patients with cancer or chronic kidney disease. Accordingly, the double-blind, placebo-controlled, randomized German Multicenter EPO Stroke Trial (Phase II/III; ClinicalTrials.gov Identifier: NCT00604630) was designed to evaluate efficacy and safety of EPO in stroke.Methods— This clinical trial enrolled 522 patients with acute ischemic stroke in the middle cerebral artery territory (intent-to-treat population) with 460 patients treated as planned (per-protocol population). Within 6 hours of symptom onset, at 24 and 48 hours, EPO was infused intravenously (40 000 IU each). Systemic thrombolysis with recombinant tissue plasminogen activator was allowed and stratified for.Results— Unexpectedly, a very high number of patients received recombinant tissue plasminogen activator (63.4%). On analysis of total intent-to-treat and per-protocol populations, neither primary outcome Barthel Index on Day 90 (P=0.45) nor any of the other outcome parameters showed favorable effects of EPO. There was an overall death rate of 16.4% (n=42 of 256) in the EPO and 9.0% (n=24 of 266) in the placebo group (OR, 1.98; 95% CI, 1.16 to 3.38; P=0.01) without any particular mechanism of death unexpected after stroke.Conclusions— Based on analysis of total intent-to-treat and per-protocol populations only, this is a negative trial that also raises safety concerns, particularly in patients receiving systemic thrombolysis."],["dc.identifier.doi","10.1161/STROKEAHA.109.564872"],["dc.identifier.gro","3150483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7252"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.subject","clinical trial; hematopoietic growth factor; neuroprotection; NIHSS; rtPA"],["dc.title","Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","879"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Archives of General Psychiatry"],["dc.bibliographiccitation.lastpage","888"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Begemann, Martin"],["dc.contributor.author","Grube, Sabrina"],["dc.contributor.author","Papiol, Sergi"],["dc.contributor.author","Malzahn, Dörte"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Ribbe, Katja"],["dc.contributor.author","Friedrichs, Heidi"],["dc.contributor.author","Radyushkin, Konstantin"],["dc.contributor.author","El-Kordi, Ahmed"],["dc.contributor.author","Benseler, Fritz"],["dc.contributor.author","Hannke, Kathrin"],["dc.contributor.author","Sperling, Swetlana"],["dc.contributor.author","Schwerdtfeger, Dayana"],["dc.contributor.author","Thanhäuser, Ivonne"],["dc.contributor.author","Gerchen, Martin Fungisai"],["dc.contributor.author","Ghorbani, Mohammed"],["dc.contributor.author","Gutwinski, Stefan"],["dc.contributor.author","Hilmes, Constanze"],["dc.contributor.author","Leppert, Richard"],["dc.contributor.author","Ronnenberg, Anja"],["dc.contributor.author","Sowislo, Julia"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Stödtke, Maren"],["dc.contributor.author","Szuszies, Christoph"],["dc.contributor.author","Reim, Kerstin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Eckstein, Fritz"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Bickeböller, Heike"],["dc.contributor.author","Nave, Klaus-Armin"],["dc.contributor.author","Brose, Nils"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:57Z"],["dc.date.available","2017-09-07T11:46:57Z"],["dc.date.issued","2010"],["dc.description.abstract","Context: Schizophrenia is the collective term for a heterogeneous group of mental disorders with a still obscure biological basis. In particular, the specific contribution of risk or candidate gene variants to the complex schizophrenic phenotype is largely unknown. Objective: To prepare the ground for a novel “phenomics” approach, a unique schizophrenia patient database was established by GRAS (Göttingen Research Association for Schizophrenia), designed to allow association of genetic information with quantifiable phenotypes. Because synaptic dysfunction plays a key role in schizophrenia, the complexin 2 gene (CPLX2) was examined in the first phenotype-based genetic association study (PGAS) of GRAS. Design: Subsequent to a classic case-control approach, we analyzed the contribution of CPLX2 polymorphisms to discrete cognitive domains within the schizophrenic population. To gain mechanistic insight into how certain CPLX2 variants influence gene expression and function, peripheral blood mononuclear cells of patients, Cplxnull mutantmice, and transfected cells were investigated.Setting: Coordinating research center (Max Planck Institute of Experimental Medicine) and 23 collaboratingpsychiatric centers all over Germany.Participants: One thousand seventy-one patients with schizophrenia (DSM-IV) examined by an invariant investigator team, resulting in the GRAS database with more than 3000 phenotypic data points per patient, and 1079 healthy control subjects of comparable ethnicity.Main Outcome Measure: Cognitive performance including executive functioning, reasoning, and verbal learning/memory. Results: Six single-nucleotide polymorphisms, distributed over the whole CPLX2 gene, were found to be highly associated with current cognition of schizophrenic subjects but only marginally with premorbid intelligence. Correspondingly, in Cplx2-null mutant mice, prominent cognitive loss of function was obtained only in combination with a minor brain lesion applied during puberty, modeling a clinically relevant environmental risk (“second hit”) for schizophrenia. In the human CPLX2 gene, 1 of the identified 6 cognition-relevant single-nucleotide polymorphisms, rs3822674 in the 3´ untranslated region, was detected to influence microRNA-498 binding and gene expression. The same marker was associated with differential expression of CPLX2 in peripheral blood mononuclear cells. Conclusions: The PGAS allows identification of markerassociated clinical/biological traits. Current cognitive performance in schizophrenic patients is modified by CPLX2 variants modulating posttranscriptional gene expression"],["dc.identifier.doi","10.1001/archgenpsychiatry.2010.107"],["dc.identifier.fs","577608"],["dc.identifier.gro","3150567"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6097"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7343"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","final"],["dc.rights.access","closedAccess"],["dc.subject","Schizophrenia"],["dc.subject.ddc","610"],["dc.title","Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]